Perspective Therapeutics
CATX | AMEX
$0.94
$0.00 (-0.33%)
At close: Nov 16, 2026, 3:59 PM ET
$0.96
+$0.02 (+1.79%)
After-hours:
Nov 16, 2026, 7:18 PM ET
-0.33%
(1D)No price chart data available for 1D timeframe.
Rating
25
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #928/1021 (Top 91%)
Key Statistics
Market Data
Market Cap $114.09M
1D Range
0.90 1.02
52W Range
0.79 5.65
Valuation (TTM)
PE -0.64
PB 0.39
EV/EBITDA 0.69
Valuation (NTM)
Forward PE N/A
Forward PEG 0.03
Price Target $7.50
Cash Flow
FCF Yield -121.7%
SBC Adj. FCF Yield -131.3%
SBC Impact -8.0%
Margins
Gross Margin -536.2%
Operating Margin -74402.8%
FCF Margin -78412.4%
Growth (CAGR)
Revenue 3Y | 5Y -69.7% |
-55.6%
Dil EPS 3Y | 5Y -18.0% |
-23.7%
FCF 3Y | 5Y -51.5% |
-51.7%
Returns
ROA -33.6%
ROE -41.9%
ROIC -40.0%
Financial Health
Net Cash
$200.17M
Current Ratio 5.18
Interest Coverage -331.72
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical produc...
Sector Healthcare
Industry Medical - Devices
Employees 165
IPO Date Nov 10, 2005
Website www.perspectivetherapeutics.com
Fiscal Year July - June
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 9, 2026
EPS
-$0.27
Miss -11.27%
YoY:
+22.86% REV
$20K
Miss -64.60%
YoY:
-90.43%Next Earnings
Mar 15, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
9
Consensus
Buy
Price Target
$7.50
Upside
+697.87%
Buy (7)
Hold (2)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CATX